+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06737913

Evaluating Hepatic Arterial vs. Intravenous Adabrelimab Combined with Bevacizumab and Hepatic Artery FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma

Led by Sun Yat-sen University · Updated on 2026-09-25

76

Participants Needed

3

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Adabrelimab given either through hepatic arterial infusion or intravenous infusion, combined with hepatic artery FOLFOX chemotherapy and intravenous Bevacizumab as a first-line treatment for advanced hepatocellular carcinoma HCC. This phase II trial compares two methods of administering Adabrelimab to see which works better in treating this serious liver cancer stage. The study is motivated by previous findings suggesting that delivering anti-PD-L1 therapy directly to the liver might improve response rates. Participants are randomly assigned to one of two groups one receives hepatic arterial infusion of Adabrelimab plus intravenous Bevacizumab and hepatic artery infusion chemotherapy with the FOLFOX regimen the other receives intravenous Adabrelimab with the same Bevacizumab and chemotherapy treatments. Both groups undergo up to six cycles of this triple combination treatment before continuing with intravenous Adabrelimab and Bevacizumab for maintenance until disease progression or unacceptable side effects occur. During the study, participants will have tumor imaging every six weeks to assess response, along with regular monitoring for safety and side effects. Researchers will measure outcomes such as objective response rate, progression-free survival, overall survival, and duration of response over a 36-month period. Laboratory tests and clinical evaluations will ensure participants maintain adequate organ function and performance status. The total study duration extends until December 2028, with active treatment and follow-up for disease progression and adverse events.

CONDITIONS

Brief Title

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Research Team

L

Lujun Shen, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here